- Home
- GRYP vs MRKR Comparison
GRYP vs MRKR Comparison
Compare GRYP & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRYP
- MRKR
- Stock Information
- Founded
- GRYP 2010
- MRKR N/A
- Country
- GRYP United States
- MRKR United States
- Employees
- GRYP N/A
- MRKR N/A
- Industry
- GRYP
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- GRYP
- MRKR Health Care
- Exchange
- GRYP Nasdaq
- MRKR Nasdaq
- Market Cap
- GRYP 14.9M
- MRKR 13.4M
- IPO Year
- GRYP N/A
- MRKR N/A
- Fundamental
- Price
- GRYP $1.07
- MRKR $1.13
- Analyst Decision
- GRYP Hold
- MRKR Strong Buy
- Analyst Count
- GRYP 1
- MRKR 3
- Target Price
- GRYP N/A
- MRKR $13.17
- AVG Volume (30 Days)
- GRYP 26.3M
- MRKR 39.2K
- Earning Date
- GRYP 05-27-2025
- MRKR 05-27-2025
- Dividend Yield
- GRYP N/A
- MRKR N/A
- EPS Growth
- GRYP N/A
- MRKR N/A
- EPS
- GRYP N/A
- MRKR N/A
- Revenue
- GRYP $20,539,000.00
- MRKR $6,591,080.00
- Revenue This Year
- GRYP N/A
- MRKR N/A
- Revenue Next Year
- GRYP N/A
- MRKR N/A
- P/E Ratio
- GRYP N/A
- MRKR N/A
- Revenue Growth
- GRYP N/A
- MRKR 99.06
- 52 Week Low
- GRYP $0.13
- MRKR $0.95
- 52 Week High
- GRYP $1.80
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- GRYP 66.01
- MRKR 45.44
- Support Level
- GRYP $0.33
- MRKR $1.09
- Resistance Level
- GRYP $2.93
- MRKR $1.30
- Average True Range (ATR)
- GRYP 0.26
- MRKR 0.09
- MACD
- GRYP 0.08
- MRKR -0.00
- Stochastic Oscillator
- GRYP 31.03
- MRKR 19.05
About GRYP Gryphon Digital Mining Inc Common Stock
Gryphon Digital Mining Inc is a Bitcoin mining company. Gryphon's mission is to create the world's leading net carbon-neutral Bitcoin miner. The company will operate a digital asset, mining operation using specialized computers equipped with application-specific integrated circuit (ASIC) chips to solve complex cryptographic algorithms in support of the Bitcoin blockchain in exchange for cryptocurrency rewards (primarily Bitcoin).
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.